Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study.
Eder P, Kłopocka M, Cichoż-Lach H, Talar-Wojnarowska R, Kopertowska-Majchrzak M, Michalak A, Filip R, Waszak K, Stawczyk-Eder K, Janiak M, Skrobot K, Liebert A, Zatorski H, Solarska-Półchłopek A, Krogulecki M, Pękała A, Poniewierka E, Smoła I, Kaczka A, Wojciechowski K, Drygała S, Zagórowicz E.
Eder P, et al. Among authors: pekala a.
Therap Adv Gastroenterol. 2023 Feb 14;16:17562848231151295. doi: 10.1177/17562848231151295. eCollection 2023.
Therap Adv Gastroenterol. 2023.
PMID: 36818601
Free PMC article.